Oxervate
The first FDA approved pharmacological therapy for the treatment of Neurotrophic Keratitis.
Share Now
Additional Information
| Name | OXERVATE |
| Description | The first FDA approved pharmacological therapy for the treatment of Neurotrophic Keratitis |
| Active Ingredient | Cenegermin-bkbj |
| Indication | |
| Treatment of Neurotrophic Keratiti | |
| Strengths | 0.002% 20 mcg/ ml |
| Regulatory Status | Registered |
| Business Partner | Dompe Farmaceutici |
| Origin | Italy |
Related Products
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.
